Nasdaq

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib 1 In the ...
Benzinga.com

Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients

On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
Monthly Prescribing Reference

Opdivo + Yervoy Approved as First-Line Tx for Hepatocellular Carcinoma

The immunotherapy combination significantly improved overall survival compared with lenvatinib or sorafenib. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...
Nasdaq

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO) +TKI ...